Palatin Provides Update on Anticipated 2025 Corporate Milestones

Core Insights - Palatin Technologies, Inc. is preparing for a significant year in 2025, focusing on the topline data from its Phase 2 BMT-801 clinical study, which evaluates the combination of bremelanotide and tirzepatide for obesity treatment, with results expected in the first quarter of 2025 [2][5][6] - The company aims to initiate multiple clinical trials in the second half of 2025 for a long-acting MC4R peptide and/or an MC4R selective oral small molecule targeting general obesity and related conditions [2][5] - Palatin has a strong position in the melanocortin receptor system (MCRS) development, with extensive intellectual property and a library of compounds for developing MC4R agonists [2][8] Obesity Programs - The Phase 2 BMT-801 clinical study is designed to demonstrate the safety and efficacy of bremelanotide combined with tirzepatide in reducing body weight, with topline results anticipated in Q1 2025 [5][6] - The company is targeting general obesity, weight loss management, and rare neuroendocrine and genetic diseases, including hypothalamic obesity, with plans for IND enabling activities to start in Q1 2025 and IND filings expected in the second half of 2025 [6][8] - Multiple clinical trials for new MC4R compounds are planned to commence in the second half of 2025 [5][6] Other Programs - Ongoing discussions for licensing and collaboration related to dry eye disease, ulcerative colitis, and diabetic nephropathy programs, with multiple deals targeted for 2025 [5][6] - Positive outcomes from a Type C meeting with the FDA regarding endpoints for Phase 3 trials in dry eye disease, with patient enrollment set to begin in the first half of 2025 [6][7]